As a leader in the field of Intrauterine Contraceptive Devices or IUD Embry Women’s Health specializes in bringing the benefits of the IUD device to women of all ages.

An intrauterine device (IUD) is a type of birth control placed inside the lining of the uterus. JoEllen Embry, WHNP, and Barbara Lockwood, WHNP, of Embry Women’s Health offer IUDs to women in Mesa, AZ and Tempe, AZ, as well as the surrounding area. Women can make an appointment to discuss IUDs by scheduling an appointment online with Embry Women’s Health today.

Five types of intrauterine devices are currently available in the United States. These include the Mirena IUD, Skyla, IUD, Kyleena IUD, Liletta IUD and the Paragard IUD. Each device is slightly different allowing the right device for the right patient. The IUD specialists at Embry Women’s Health will guide you on the path to selecting the right IUD.

• Mirena^® is a levonorgestrel-releasing IUD 52 mg that is over 99% effective at preventing pregnancy for as long as you want, for up to 5 years.
• Skyla^® is a levonorgestrel-releasing IUD 13.5 mg that is over 99% effective at preventing pregnancy for as long as you want, for up to 3 years. It is estrogen-free.
• Kyleena^® is a levonorgestrel-releasing IUD 19.5 mg that is over 99% effective at preventing pregnancy for as long as you want, for up to 5 years.
• Liletta^® is a levonorgestrel-releasing IUD 52 mg that is over 99% effective at preventing pregnancy for as long as you want, for up to 5 years.
• Paragard is a copper-releasing IUD device that is over 99% effective at preventing pregnancy for as long as you want, for up to 10 years. It is the only IUD device that is 100% hormone-free.

As a leader in the field of Hereditary Cancer testing Embry Women’s Health specializes in bringing the benefits of 25-gene panel testing to everyone.

Myriad myRisk is a scientific advancement that will revolutionize hereditary cancer testing and patient care. Myriad myRisk blends genetic testing status and personal/family cancer history into clinically actionable risk assessment and follow-up. This provides clear and actionable direction for the patient. The Myriad myRisk report provides recommendations for managing either positive or negative genetic results.